Behavioral Health is Essential To Health

Prevention Works

Treatment is Effective

People Recover
Introductory Remarks

SAMHSA’s
Center for Substance Abuse Prevention
Drug Testing Advisory Board

Ron Flegel, BSMT(ASCP), MS.
DTAB Chair

June 13, 2017
Public Session
Mandatory Guidelines

- Urine
  - Published in Federal Register January 23, 2017
    - 82 FR 7920, Pages 7920-7970
  - Effective date: October 1, 2017
  - Changes
    - Synthetic Opioids: oxycodone, oxymorphone, hydrocodone, and hydromorphone
    - Removed MDEA
    - Added MDA as initial testing analyte
    - Raised lower pH cutoff for determining an adulterated specimen [3 → 4]
  - DOT NRPM published January 23, 2017
National Laboratory Certification Program

- Implementation of UrMG
  - Revising Program Documents
    - NLCP Manual, NLCP Checklist, Application, C-Tables (August 2017)
    - Fed Agency Collection Site Assessment documents
  - Implementation PTs
    - Qualifying PTs – 3 Sets (May 1, June 12, July 24, 2017)
    - Verification PTs - Post Implementation (October 9, 2017)
- Drug Program Coordinator Training
- Inspector Training (September 2017)
National Laboratory Certification Program

- PT cycles
  - Urine – Integrate new analytes and pH change into quarterly PT’s as of January 2018
  - Oral Fluid – 3 Occasions including new analytes beginning January 2018
  - Hair – Continue to develop inventory of user hair specimens
Drug Free Workplace Program

- DWP continues to brief agency Drug Program Coordinators and Senior Leadership on upcoming changes
- Implementation of Revised Mandatory Guidelines – Urine
  - October 1, 2017
- DWP Interagency Coordinating Group Briefing
  - June meeting has been postponed
  - Web / Teleconference tentatively scheduled for late August or early September 2017
Agency Briefing

• September 2017
• Webinar attendance
• Agenda:
  • Scientific background and implications of testing for synthetic opiates
  • Status of oral fluids testing
  • Studies and progress toward inclusion of other alternative matrices
  • Electronic Chain of Custody Form (E-CCF)
  • Annual Survey Report (ASR) - reporting of federal data
  • Next steps for agencies and Drug Program Coordinators
Mandatory Guidelines

• Oral Fluid
  • Currently under final review by SAMHSA / HHS

• Hair
  • Mandatory Guidelines for Federal Workplace Drug Testing using Hair is under review - comments from DTAB and HHS are being considered.
  • DTAB Recommendation on hair is currently being addressed: decontamination and hair color impact
Ongoing Studies

- Cannabidiol Study
  - Tentative start time: August 2017
- Pharmacokinetics and Pharmacodynamics Study: oral, smoked, and vaporized cannabis
  - SOFT 2017: 2 Presentations
    - Disposition of Cannabinoids in Oral Fluid and Whole Blood after Vaporized and Smoked Cannabis
    - Pharmacodynamic Comparison of Acute Cannabis Effects Following Oral, Smoked, and Vaporized Administration
- Unique Metabolites in Hair
  - SOFT 2017: 1 presentation (opioid glucuronides)
    - Detection and Quantification by LC-MS/MS of Opioid Glucuronides in Hair of Opioid Users.
DTAB Questions

Questions from the DTAB Advisory Board?